Approche chimioprotéomique pour la déconvolution des cibles du MG624 dans les cellules AML

Synthèse et optimisation d'inhibiteurs spécifiques de ERK3 pour le développement d'une thérapie ciblée au cancer du sein triple-négatif

Reduced collision fingerprints and pairwise molecular comparisons for explainable property prediction using Deep Learning

Synthèse de composés outils permettant l’approfondissement des connaissances biologiques dans le domaine oncologique

Mechanisms of action of antiestrogens in breast cancer: roles of ubiquitin-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Architecture and chemical modulation of genetic networks

PandemicStop-AI: for an accelerated response to pandemics

PandemicStop-AI: for an accelerated response to pandemics

RAS-MAPK signal transduction in normal and cancer cells

Distilled-DEL: A novel DNA-encoded drug discovery platform enabling biological evaluation of cellular targets on live cells.

Deciphering metabolic vulnerabilites to improve therapeutic strategies in low survival cancers

The Eastern Canada Preparedness Hub - ECaPH

Development of a novel cyclin K degrader of high-risk AML patients and associated genomic features - Genomic Applications Partnership Program (GAPP)

Development of a novel cyclin K degrader of high-risk AML patients and associated genomic features - Genomic Applications Partnership Program (GAPP)

Médicament Québec - Partenariat en Découverte et Production de Médicament du Québec

CECR_IRICoR_Advanced pre-clinical development of first-in-class covalent Yes/Src inhibitors for cancer treatment

CECR_IRICoR_DUSP4/6 and KSR1/2 as potential targets in cancer

Mechanisms of action of antiestrogens in breast cancer: roles of Ubi-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Designing a toolbox of paradigmatic treatments for a targeted molecular medicine approach to autosomal-recessive ataxias

Designing a toolbox of paradigmatic treatments for a targeted molecular medicine approach to autosomal-recessive ataxias

Examining chemical modulation of kinesin-13 activities: From mechanism to validation

The Acuity-Qc consortium: predicting and imaging drug action) / Sous-projet # 1 « AI-augmented DEL technology »

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Development of Electron Transport Chain (ETC) complex I inhibitors as poor outcome AML treatment

FI - Recruitment of SUMO E3 ligases as a new paradigm for transcription factor inactivation

FD - Recruitment of SUMO E3 ligases as a new paradigm for transcription factor inactivation

The Acuity-Qc consortium: predicting and imaging drug action) / Sous-projet # 1 « AI-augmented DEL technology »

The Acuity-Qc consortium: predicting and imaging drug action) / Sous-projet # 1 « AI-augmented DEL technology »

The Acuity-Qc consortium: predicting and imaging drug action) / Sous-projet # 1 « AI-augmented DEL technology »

Interrogating and implementing Omics for precision medicine in Acute Myeloid Leukemia.

Development of small molecule modulators of Ras signaling

Développement d'une série inédite d'inhibiteurs des GTPases RAS

Designing a toolbox of paradigmatic treatments for a targeted molecular medicine approach to autosomal-recessive ataxias

Identification of lead compounds for modulation of Nur77 /RXR receptor complex activity in the management of L-Dopa-induced dyskinesia in Parkinson's disease

Development of orally bioavailable antiestrogens optimized for induction of estrogen receptor post-translational modifications by SUMOylation

Développement d'une série inédite d'inhibiteurs des GTPases RAS

Identification and preclinical development of small molecule inhibitors of the cancer-related ubiquitin-conjugating enzyme UBCH10

Interrogating and implementing Omics for precision medicine in Acute Myeloid Leukemia

Protac UM171

Développement d'une série inédite d'inhibiteurs des GTPases RAS

Développement d'une série inédite d'inhibiteurs des GTPases RAS

Protac UM171

Établissement d'un pipeline de criblage chimiogénomique pour les leucémies pédiatriques à haut risque

Établissement d'un pipeline de criblage chimiogénomique pour les leucémies pédiatriques à haut risque

Collaboration IRIC / universités / industrie : découverte accélérée de thérapies de l'économie pour un impact durable - FACS

Interrogating and implementing Omics for precision medicine in Acute Myeloid Leukemia

Development of new technology for the synthesis of DNA-encoded libraries

RUNX1 mutations that confer exquisite sensitivity to glucocorticoids

Développement de nouveaux composés fonctionnellement sélectifs ciblant FPR2 (Formyl Peptide Receptor 2)

UNE APPROCHE CHIMIO- ET PROTEO-GENOMIQUE EN MEDECINE PERSONNALISEE POUR LA LEUCEMIE MYELOIDE AIGUE

Développement de Grappes de Corrélation de Composés (GCC) pour l'identification de nouvelles cibles en LMA

Développement de Grappes de Corrélation de Composés (GCC) pour l'identification de nouvelles cibles en LMA

Développement de nouveaux composés fonctionnellement sélectifs ciblant le FPR2 (Formyl Peptide Receptor 2)

Development of first-in-class small molecule inhibitors of a cancer-related ubiquitin-conjugating enzyme

Development of hematopoietic stem cell expanding molecules towards the ideal transplant

Development of hematopoietic stem cell expanding molecules towards the ideal transplant

INNOVATIVE CHEMOGENOMIC TOOLS TO IMPROVE OUTCOME IN ACUTE MYELOID LEUKEMIA

INNOVATIVE CHEMOGENOMIC TOOLS TO IMPROVE OUTCOME IN IN ACUTE MYELOID LEUKEMIA

INNOVATIVE CHEMOGENOMIC TOOLS TO IMPROVE OUTCOME IN ACUTE MYELOID LEUKEMIA

M171 GMP PRODUCTION FOR CLINICAL TRIAL TO EXPAND HUMAN CORD BLOOD STEM CELLS